A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

NCT03390504 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

629

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Cancer

Interventions

DRUG: Erdafitinib
DRUG: Vinflunine
DRUG: Docetaxel
DRUG: Pembrolizumab
DEVICE: Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)

Sponsor

Janssen Research & Development, LLC